{"log_id": 6986348061006489487, "direction": 0, "words_result_num": 43, "words_result": [{"probability": {"variance": 0, "average": 0.999765, "min": 0.999359}, "location": {"width": 68, "top": 185, "height": 26, "left": 221}, "words": "【禁忌】"}, {"probability": {"variance": 3e-06, "average": 0.998836, "min": 0.993145}, "location": {"width": 507, "top": 218, "height": 36, "left": 256}, "words": "本品禁用于已知对利奈唑胺或本品其他成分过敏的患者"}, {"probability": {"variance": 2.5e-05, "average": 0.99656, "min": 0.985184}, "location": {"width": 172, "top": 253, "height": 27, "left": 207}, "words": "单胺氧化酶抑制剂"}, {"probability": {"variance": 2e-06, "average": 0.999191, "min": 0.994546}, "location": {"width": 809, "top": 287, "height": 37, "left": 250}, "words": "正在使用任何能抑制单胺氧化酶A或B的药物(如:苯乙肼、异卡波肼)的患者,或两"}, {"probability": {"variance": 3e-06, "average": 0.998795, "min": 0.993921}, "location": {"width": 465, "top": 321, "height": 30, "left": 206}, "words": "周内曾经使用过这类药物的患者不应使用利奈唑胺"}, {"probability": {"variance": 1e-06, "average": 0.998924, "min": 0.995517}, "location": {"width": 277, "top": 356, "height": 28, "left": 206}, "words": "引起血压升高的潜在相互作用"}, {"probability": {"variance": 9e-06, "average": 0.998821, "min": 0.981576}, "location": {"width": 813, "top": 389, "height": 37, "left": 245}, "words": "除非能够对于患者可能出现的血压升高进行监测,否则利奈唑胺不应用于存在以下潜在"}, {"probability": {"variance": 0, "average": 0.999599, "min": 0.997984}, "location": {"width": 399, "top": 420, "height": 35, "left": 203}, "words": "临床状况或同时使用以下类型药物的患者"}, {"probability": {"variance": 2e-06, "average": 0.999034, "min": 0.993376}, "location": {"width": 815, "top": 455, "height": 37, "left": 244}, "words": "高血压未控制的患者、嗜铬细胞瘤、类癌、甲状腺机能亢进、双相抑郁、分裂情感性精"}, {"probability": {"variance": 0, "average": 0.999753, "min": 0.999136}, "location": {"width": 374, "top": 490, "height": 28, "left": 248}, "words": "神障碍或处于急性意识模糊状态的患者"}, {"probability": {"variance": 0.000529, "average": 0.991833, "min": 0.890526}, "location": {"width": 806, "top": 522, "height": 35, "left": 242}, "words": "使用以下任何药物的患者:5-羟色胺再摄取抑制剂、三环类抗抑郁药、5-羟色胺5-HT"}, {"probability": {"variance": 0.000125, "average": 0.996368, "min": 0.944446}, "location": {"width": 801, "top": 553, "height": 39, "left": 245}, "words": "受体激动剂(曲普坦类)、直接或间接拟交感神经药物(包括肾上腺素支气管扩张药"}, {"probability": {"variance": 5e-06, "average": 0.998538, "min": 0.989866}, "location": {"width": 813, "top": 586, "height": 39, "left": 245}, "words": "伪麻黄碱和去甲麻黄碱)、血管加压药物(如:肾上腺素、去甲肾上腺素),多巴胺类药"}, {"probability": {"variance": 0.000143, "average": 0.996409, "min": 0.923649}, "location": {"width": 800, "top": 621, "height": 34, "left": 242}, "words": "物(如:多巴胺、多巴酚丁胺)、哌替啶或丁螺环酮(见【注意事项】、【药物相互作用】"}, {"probability": {"variance": 9e-06, "average": 0.998869, "min": 0.982242}, "location": {"width": 818, "top": 652, "height": 37, "left": 239}, "words": "动物数据表明,利奈唑胺及其代谢产物可进入乳汁,因此使用本品治疗之前和期间应"}, {"probability": {"variance": 2.5e-05, "average": 0.99839, "min": 0.978172}, "location": {"width": 399, "top": 686, "height": 30, "left": 196}, "words": "停止哺乳(见【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 6e-06, "average": 0.998283, "min": 0.993605}, "location": {"width": 323, "top": 719, "height": 29, "left": 197}, "words": "与5羟色胺类药物潜在的相互作用"}, {"probability": {"variance": 0.003928, "average": 0.984126, "min": 0.696977}, "location": {"width": 822, "top": 751, "height": 36, "left": 235}, "words": "除非密切观察患者5-羟色胺综合征的体征和/或症状,否则利奈唑胺不应用于类癌综合征"}, {"probability": {"variance": 0.001532, "average": 0.987116, "min": 0.821993}, "location": {"width": 862, "top": 783, "height": 35, "left": 194}, "words": "的患者和/或使用任何以下药物的患者:5-羟色胺再摄取抑制剂,三环类抗抑郁药,5-羟色胺"}, {"probability": {"variance": 0.000526, "average": 0.992365, "min": 0.87494}, "location": {"width": 856, "top": 814, "height": 38, "left": 201}, "words": "-HT1受体激动剂(曲普坦类药物)、哌替啶或丁螺环酮(见【注意事项】、一般注意事项和"}, {"probability": {"variance": 1e-06, "average": 0.998581, "min": 0.997105}, "location": {"width": 156, "top": 848, "height": 27, "left": 200}, "words": "【药物相互作用】"}, {"probability": {"variance": 1e-06, "average": 0.99933, "min": 0.997815}, "location": {"width": 119, "top": 925, "height": 26, "left": 196}, "words": "【注意事项】"}, {"probability": {"variance": 5e-06, "average": 0.999081, "min": 0.990047}, "location": {"width": 818, "top": 958, "height": 35, "left": 236}, "words": "为减少耐药细菌的产生,并确保本品和其他抗菌药物的疗效,利奈唑胺应该仅用于治疗"}, {"probability": {"variance": 1.1e-05, "average": 0.998391, "min": 0.987464}, "location": {"width": 518, "top": 990, "height": 33, "left": 188}, "words": "或预防已经证实或者高度怀疑由细菌引起的感染性疾病"}, {"probability": {"variance": 1e-06, "average": 0.9989, "min": 0.998171}, "location": {"width": 47, "top": 1024, "height": 24, "left": 187}, "words": "警告"}, {"probability": {"variance": 2e-06, "average": 0.998515, "min": 0.994686}, "location": {"width": 822, "top": 1055, "height": 36, "left": 229}, "words": "在应用利奈唑胺的患者中有出现骨髓抑制的报道(包括贫血、白细胞减少、全血细胞减"}, {"probability": {"variance": 3e-05, "average": 0.997139, "min": 0.971163}, "location": {"width": 870, "top": 1086, "height": 38, "left": 185}, "words": "少和血小板减少)。在已知转归的病例中,停用利奈唑胺后血象指标可以上升并回复到治疗前"}, {"probability": {"variance": 0.000119, "average": 0.995726, "min": 0.936388}, "location": {"width": 868, "top": 1117, "height": 40, "left": 183}, "words": "的水平。出现这些影响的风险似乎与疗程有关。使用利奈唑胺治疗的老年患者出现血恶液质"}, {"probability": {"variance": 4.9e-05, "average": 0.997708, "min": 0.955459}, "location": {"width": 869, "top": 1150, "height": 38, "left": 182}, "words": "的风险高于年轻患者。血小板减少在严重肾功能不全(无论是否正在接受透析)患者中更常"}, {"probability": {"variance": 0, "average": 0.999641, "min": 0.999641}, "location": {"width": 25, "top": 1185, "height": 24, "left": 183}, "words": "见"}, {"probability": {"variance": 1e-05, "average": 0.997398, "min": 0.984602}, "location": {"width": 831, "top": 1217, "height": 36, "left": 222}, "words": "对应用利奈唑胺的患者应每周进行全血细胞计数的检查,尤其是那些用药超过两周,或"}, {"probability": {"variance": 3.9e-05, "average": 0.997986, "min": 0.960757}, "location": {"width": 857, "top": 1249, "height": 36, "left": 181}, "words": "用药前已有贫血、粒细胞减少、血小板减少、骨髓抑制,或合并应用可降低血红蛋白水平"}, {"probability": {"variance": 3e-06, "average": 0.998666, "min": 0.992746}, "location": {"width": 870, "top": 1281, "height": 38, "left": 179}, "words": "抑制白细胞计数、对血小板计数或功能产生不良影响、能导致骨髓抑制的其他药物,患有严"}, {"probability": {"variance": 0.000148, "average": 0.996676, "min": 0.921631}, "location": {"width": 874, "top": 1314, "height": 39, "left": 177}, "words": "重肾功能不全的患者;接受治疗10-14天以上的患者或患慢性感染既往或目前合并接受其他"}, {"probability": {"variance": 9.9e-05, "average": 0.995534, "min": 0.948228}, "location": {"width": 874, "top": 1347, "height": 38, "left": 176}, "words": "抗生素治疗的患者。只有在可以密切监测血红蛋白水平、白细胞计数和血小板计数的情况下"}, {"probability": {"variance": 2.9e-05, "average": 0.995726, "min": 0.981435}, "location": {"width": 265, "top": 1381, "height": 28, "left": 175}, "words": "这些患者才能使用利奈唑胺"}, {"probability": {"variance": 9e-06, "average": 0.997242, "min": 0.989986}, "location": {"width": 831, "top": 1414, "height": 37, "left": 218}, "words": "对发生骨髓抑制或骨髓抑制发生恶化的患者应考虑停用利奈唑胺治疗。除非绝对有必要"}, {"probability": {"variance": 3e-06, "average": 0.998965, "min": 0.992521}, "location": {"width": 717, "top": 1447, "height": 35, "left": 173}, "words": "继续治疗,在此情况下应更频繁地监测血细胞计数并采取适当的处理策略。"}, {"probability": {"variance": 8e-06, "average": 0.998006, "min": 0.986844}, "location": {"width": 833, "top": 1479, "height": 40, "left": 216}, "words": "此外建议,应每周监测接受利奈唑胺的患者的全血细胞计数(包括血红蛋白水平、血小"}, {"probability": {"variance": 2e-06, "average": 0.998602, "min": 0.995435}, "location": {"width": 603, "top": 1513, "height": 36, "left": 171}, "words": "板、白细胞总数和分类计数),不论其基线血细胞计数情况如何"}, {"probability": {"variance": 2.3e-05, "average": 0.997746, "min": 0.98003}, "location": {"width": 837, "top": 1579, "height": 38, "left": 212}, "words": "在同情性使用研究中,利奈唑胺疗程超过最长推荐的28天时会增加严重贫血发生率。这"}, {"probability": {"variance": 3e-06, "average": 0.997892, "min": 0.994858}, "location": {"width": 153, "top": 1628, "height": 24, "left": 530}, "words": "第12页,共29页"}, {"probability": {"variance": 0.032413, "average": 0.855883, "min": 0.509963}, "location": {"width": 116, "top": 1656, "height": 23, "left": 546}, "words": "辉瑞——机密"}], "language": 3}